Scammer, share you concerns definitely but can see the reasoning. Of course they would definitely wait for sales data/acutal revenue and Ph111 trial results (presumably) before splitting, with a stated intention for the demerger being sometime in 1H 2012.
With the unlisted options it also means that on listing ACL Oncology should get a capital injection assuming the options are exercised, as mentioned above.
The more I think about it the more I can see the reasoning-even the threat of a split should make the market start to think about the value of the Fonda revenue stream rated by itself as a revenue/dividend stream rather than something being used to fund risky development pipelines.
Execution risk is a worry still but lets not forget theres nothing to say ACL must demerge if the market's valuation improves.
- Forums
- ASX - By Stock
- TSN
- capital raising
capital raising, page-116
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online